A Phase 2 interventional study of CINRYZE with rHuPH20 in Hereditary Angioedema (HAE), sponsored by Shire. Completed at 23 sites in 4 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-06-03.
Sponsored by Shire (part of Takeda) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing C1 esterase inhibitor (human) in Angioedemas, Hereditary — 1 open to participants now, 1 under way, none of them phase 3. C1 esterase inhibitor (human) · Angioedemas, Hereditary.
Among the 11 studies testing C1 esterase inhibitor (human) in Angioedemas, Hereditary, this one is the 5th largest by enrollment, is the only one that started in 2013, is one of 8 in phase 2, and was the 8th registered.
171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.
Browse Angioedemas, Hereditary studies →1 of the 11 studies testing C1 esterase inhibitor (human) in Angioedemas, Hereditary is open now, in 1 country. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–75
By country, each count listing its studies:
C1 esterase inhibitor (human): first FDA approval 2008 (Cinryze), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 9 · Phase 3 2 · Phase 4 1
First in 2004; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 47 is close to the median of 48 across 116 interventional studies indexed under Angioedemas, Hereditary.
Median enrollment 32 across the 11 interventional studies. Of the 9 that completed or were terminated, 9 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 4 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
58 studies in Angioedemas, Hereditary by Takeda: 3 open now, 4 under way, none of them phase 3. Of 52 finished, 33 (63%) have results posted.
Among the 58 studies in Angioedemas, Hereditary by Takeda, this one is the 17th largest by enrollment of the 36 interventional ones that give a count, is one of 2 that started in 2013, is one of 5 in phase 2, and was the 23rd registered.
Takeda’s Angioedemas, Hereditary studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing C1 esterase inhibitor (human) in Angioedemas, Hereditary, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 58 in Angioedemas, Hereditary:
This tab as a report to print or save as PDF → With an account.
The primary objectives of the study are to evaluate the safety, tolerability, and efficacy of two doses of CINRYZE with recombinant human hyaluronidase (rHuPH20) administered by subcutaneous (SC) injection to prevent angioedema attacks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SC CINRYZE with rHuPH20 Dose Level 1 twice weekly (every 3 or 4 days) for 8 weeks followed by SC CINRYZE with rHuPH20 Dose Level 2 twice weekly (every 3 or 4 days) for 8 weeks.
Biological: CINRYZE with rHuPH20
SC CINRYZE with rHuPH20 Dose Level 2 twice weekly (every 3 or 4 days) for 8 weeks followed by SC CINRYZE with rHuPH20 Dose Level 1 twice weekly (every 3 or 4 days) for 8 weeks.
Biological: CINRYZE with rHuPH20
Drug pages: C1 esterase inhibitor (human) · Hyaluronidase (human recombinant)
Also known as: C1 esterase inhibitor (human), Recombinant human hyaluronidase
Normalized Number of Angioedema Attacks During the Treatment Period
Angioedema attack was defined as the participant-reported indication of symptoms or signs such as swelling or pain at any location following a report of no swelling or pain on the previous day. Manifestations of an attack that progress from one site to another, prior to complete resolution, was considered a single attack. Attacks that began to regress and then worsened before complete resolution was also considered one attack. Participants who were dosed but did not have any attacks in the period were assigned a value of zero. The number of attacks was normalized for the number of days participants participated in a given period and expressed as the monthly frequency.
Time frame: From Visit 1 (Week 1) up to Visit 16 (Week 8) during each treatment period
Cumulative Attack-severity During the Treatment Period
Cumulative Attack-severity score was the sum of maximum symptom severity recorded for each angioedema attack, determined on the last day of symptoms and recorded as None=0, Mild=1, Moderate=2, and Severe=3 and summing over the unique attacks, yields a Cumulative Attack-severity score. None: no angioedema attack symptom; Mild: the angioedema attack symptom was noticeable to the participant but was easily tolerated and did not interfere with routine activities; Moderate: the angioedema attack symptom interfered with work/school or the ability to participate in family life and social activities; Severe: the angioedema attack symptom significantly limited the participant's ability to attend work/school or participate in family life and social activities. Cumulative attack-severity was normalized for the number of days participants participated in a given period and expressed as the monthly frequency. The scores ranged from 0 to 168 and higher scores represent worse symptoms.
Time frame: From Visit 1 (Week 1) up to Visit 16 (Week 8) during each treatment period
Cumulative Daily-severity During the Treatment Period
Cumulative Daily-severity score was the sum of the severity scores recorded for every day of reported symptoms during the treatment period. Severity scores were recorded as None=0, Mild=1, Moderate=2, and Severe=3. None: no angioedema attack symptom; Mild: the angioedema attack symptom was noticeable to the participant but was easily tolerated and did not interfere with routine activities; Moderate: the angioedema attack symptom interfered with work/school or the ability to participate in family life and social activities; Severe: the angioedema attack symptom significantly limited the participant's ability to attend work/school or participate in family life and social activities. Cumulative daily severity was normalized for the number of days participants participated in a given period and expressed as the monthly frequency. The scores ranged from 0 to 168 and higher scores represent worse symptoms.
Time frame: From Visit 1 (Week 1) up to Visit 16 (Week 8) during each treatment period
Cumulative Symptomatic Days During the Treatment Period
Cumulative symptomatic days was defined as the sum of the symptomatic days of each angioedema attack reported during the treatment period. Participants who were dosed but did not have any attacks in the period were assigned a value of zero. Cumulative symptomatic days was normalized for the number of days participants participated in a given period and expressed as the monthly frequency.
Time frame: From Visit 1 (Week 1) up to Visit 16 (Week 8) during each treatment period
Number of Angioedema Attacks Requiring Acute Treatment During the Treatment Period
Angioedema attack was defined as the participant-reported indication of symptoms or signs such as swelling or pain at any location following a report of no swelling or pain on the previous day. Manifestations of an attack that progress from one site to another, prior to complete resolution, was considered a single attack. Attacks that began to regress and then worsened before complete resolution was also considered one attack. Participants who were dosed but did not have any attacks in the period were assigned a value of zero. The number of attacks was normalized for the number of days participants participated in a given period and expressed as the monthly frequency.
Time frame: From Visit 1 (Week 1) up to Visit 16 (Week 8) during each treatment period
This study was conducted at 24 sites (United States=20, Europe=4) between 04 February 2013 (first participant dosed) and 13 September 2013 (last participant contact). Of 52 screened participants, 47 were randomized and treated. Screen failure reasons were consent withdrawn by 1 participant and violation of eligibility criteria by 4 participants.
| Milestone | Treatment Sequence A/B | Treatment Sequence B/A |
|---|---|---|
| Started | 23 | 24 |
| Completed | 22 | 22 |
| Not completed | 1 | 2 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Milestone | Treatment Sequence A/B | Treatment Sequence B/A |
|---|---|---|
| Started | 22 | 22 |
| Completed | 22 | 22 |
| Not completed | 0 | 0 |
| Milestone | Treatment Sequence A/B | Treatment Sequence B/A |
|---|---|---|
| Started | 22 | 22 |
| Completed | 22 | 22 |
| Not completed | 0 | 0 |
Angioedema attack was defined as the participant-reported indication of symptoms or signs such as swelling or pain at any location following a report of no swelling or pain on the previous day. Manifestations of an attack that progress from one site to another, prior to complete resolution, was considered a single attack. Attacks that began to regress and then worsened before complete resolution was also considered one attack. Participants who were dosed but did not have any attacks in the period were assigned a value of zero. The number of attacks was normalized for the number of days participants participated in a given period and expressed as the monthly frequency.
| angioedema attacks | Treatment A (1000 U CINRYZE + 24000 U rHuPH20) | Treatment B (2000 U CINRYZE + 48000 U rHuPH20) |
|---|---|---|
| Normalized Number of Angioedema Attacks During the Treatment Period | 1.58 (0.88 to 2.29) | 0.97 (0.41 to 1.53) |
Cumulative Attack-severity score was the sum of maximum symptom severity recorded for each angioedema attack, determined on the last day of symptoms and recorded as None=0, Mild=1, Moderate=2, and Severe=3 and summing over the unique attacks, yields a Cumulative Attack-severity score. None: no angioedema attack symptom; Mild: the angioedema attack symptom was noticeable to the participant but was easily tolerated and did not interfere with routine activities; Moderate: the angioedema attack symptom interfered with work/school or the ability to participate in family life and social activities; Severe: the angioedema attack symptom significantly limited the participant's ability to attend work/school or participate in family life and social activities. Cumulative attack-severity was normalized for the number of days participants participated in a given period and expressed as the monthly frequency. The scores ranged from 0 to 168 and higher scores represent worse symptoms.
| Score on a scale | Treatment A (1000 U CINRYZE + 24000 U rHuPH20) | Treatment B (2000 U CINRYZE + 48000 U rHuPH20) |
|---|---|---|
| Cumulative Attack-severity During the Treatment Period | 3.14 ± 3.79 | 1.81 ± 2.55 |
Cumulative Daily-severity score was the sum of the severity scores recorded for every day of reported symptoms during the treatment period. Severity scores were recorded as None=0, Mild=1, Moderate=2, and Severe=3. None: no angioedema attack symptom; Mild: the angioedema attack symptom was noticeable to the participant but was easily tolerated and did not interfere with routine activities; Moderate: the angioedema attack symptom interfered with work/school or the ability to participate in family life and social activities; Severe: the angioedema attack symptom significantly limited the participant's ability to attend work/school or participate in family life and social activities. Cumulative daily severity was normalized for the number of days participants participated in a given period and expressed as the monthly frequency. The scores ranged from 0 to 168 and higher scores represent worse symptoms.
| Score on a scale | Treatment A (1000 U CINRYZE + 24000 U rHuPH20) | Treatment B (2000 U CINRYZE + 48000 U rHuPH20) |
|---|---|---|
| Cumulative Daily-severity During the Treatment Period | 4.63 ± 5.79 | 2.81 ± 4.42 |
Cumulative symptomatic days was defined as the sum of the symptomatic days of each angioedema attack reported during the treatment period. Participants who were dosed but did not have any attacks in the period were assigned a value of zero. Cumulative symptomatic days was normalized for the number of days participants participated in a given period and expressed as the monthly frequency.
| days | Treatment A (1000 U CINRYZE + 24000 U rHuPH20) | Treatment B (2000 U CINRYZE + 48000 U rHuPH20) |
|---|---|---|
| Cumulative Symptomatic Days During the Treatment Period | 3.06 ± 3.51 | 2.14 ± 3.30 |
Angioedema attack was defined as the participant-reported indication of symptoms or signs such as swelling or pain at any location following a report of no swelling or pain on the previous day. Manifestations of an attack that progress from one site to another, prior to complete resolution, was considered a single attack. Attacks that began to regress and then worsened before complete resolution was also considered one attack. Participants who were dosed but did not have any attacks in the period were assigned a value of zero. The number of attacks was normalized for the number of days participants participated in a given period and expressed as the monthly frequency.
| angioedema attacks | Treatment A (1000 U CINRYZE + 24000 U rHuPH20) | Treatment B (2000 U CINRYZE + 48000 U rHuPH20) |
|---|---|---|
| Number of Angioedema Attacks Requiring Acute Treatment During the Treatment Period | 0.99 ± 1.51 | 0.43 ± 0.89 |
Collected over From the time of first dose of study drug up to 7 days after the last dose of study drug within each treatment period (8 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A (1000 U CINRYZE + 24000 U rHuPH20) | — | 0/44 (0%) | 42/44 (95.5%) |
| Treatment B (2000 U CINRYZE + 48000 U rHuPH20) | — | 0/46 (0%) | 46/46 (100%) |
| Event | Treatment A (1000 U CINRYZE + 24000 U rHuPH20) | Treatment B (2000 U CINRYZE + 48000 U rHuPH20) |
|---|---|---|
| Injection site reactionsGeneral disorders | 37/44 | 40/46 |
| Hereditary angioedemaCongenital, familial and genetic disorders | 32/44 | 28/46 |
| Injection site extravasationGeneral disorders | 4/44 | 9/46 |
| FatigueGeneral disorders | 4/44 | 1/46 |
| NasopharyngitisInfections and infestations | 4/44 | 1/46 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 3/44 | 2/46 |
| HeadacheNervous system disorders | 2/44 | 3/46 |
| ContusionInjury, poisoning and procedural complications | 2/44 | 0/46 |
| Chest discomfortGeneral disorders | 2/44 | 0/46 |
| Injury associated with deviceGeneral disorders | 2/44 | 0/46 |
Intent-to-treat safety (ITT-S) population included all participants who received any amount of study drug.
| Age, Continuous(years) | Entire Study Population |
|---|---|
| Mean | 39.0 ± 14.6 |
| Sex: Female, Male(Participants) | Entire Study Population |
|---|---|
| Female | 33 |
| Male | 14 |
Ran from Feb 2013 to primary completion in Sep 2013, 7 months.
Results were first posted in Jun 2015, 1 year 8 months after primary completion. A results delay was requested in Feb 2015.
Of 17 phase 2 interventional studies under Angioedemas, Hereditary, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's 7 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: C1 esterase inhibitor (human) · Hyaluronidase (human recombinant)